Hetero, Cipla's Remdesivirs Hit India Market, 'Surplus' Envisaged By August
Prices Well Below $100/vial
Executive Summary
Gilead licensees Hetero and Cipla introduce remdesivir, the antiviral seen as a potential treatment for COVID-19, in India. Pricing plans will be closely watched and supplies in the country are expected to stabilize soon, possibly turning to a surplus situation in several months.
You may also be interested in...
2021 Deal Action In India: Watch Private Equity And E-Pharmacy
Most roads led to India in 2020 when it came to deals to expand access to COVID-19 therapies, but the challenging year also saw significant private equity interest and there are expectations of more action ahead in the new year.
WHO No-Go Not A Swan Song For Remdesivir In India?
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
'Endemic' Coronavirus: Cipla Defines Sustainability Of Gains
The potentially endemic nature of the coronavirus could buoy gains for Cipla’s COVID-19 portfolio, which now includes an antibody detection kit. The Indian firm’s albuterol generic has also chipped away at market share in the US.
Need a specific report? 1000+ reports available
Buy Reports